A J Kazimi bought $881 of CPIX
Chairman and CEO at CUMBERLAND PHARMACEUTICALS INC. 168 shares at an average of $5.24, traded Mar 3, 2025, filed Apr 4, 2025.
Score components
- +25RoleCEO
- 0Trade size$881 at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- +4Price context17% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-016742, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $5.54 | $55 | 5,698,748 | Apr 4, 2025 |
| Mar 4, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $5.11 | $51 | 5,698,758 | Apr 4, 2025 |
| Mar 5, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $6.75 | $68 | 5,698,768 | Apr 4, 2025 |
| Mar 6, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $6.57 | $66 | 5,698,778 | Apr 4, 2025 |
| Mar 7, 2025 | POpen-market purchase Common Stock10b5-1 | +10 | $6.51 | $65 | 5,698,788 | Apr 4, 2025 |
| Mar 10, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.85 | $41 | 5,698,795 | Apr 4, 2025 |
| Mar 11, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $4.85 | $34 | 5,698,802 | Apr 4, 2025 |
| Mar 12, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.17 | $36 | 5,698,809 | Apr 4, 2025 |
| Mar 13, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.47 | $38 | 5,698,816 | Apr 4, 2025 |
| Mar 14, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.38 | $38 | 5,698,823 | Apr 4, 2025 |
| Mar 17, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.41 | $38 | 5,698,830 | Apr 4, 2025 |
| Mar 18, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.12 | $36 | 5,698,837 | Apr 4, 2025 |
| Mar 19, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.41 | $38 | 5,698,844 | Apr 4, 2025 |
| Mar 20, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $5.07 | $35 | 5,698,851 | Apr 4, 2025 |
| Mar 21, 2025 | POpen-market purchase Common Stock10b5-1 | +7 | $4.89 | $34 | 5,698,858 | Apr 4, 2025 |
| Mar 24, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.42 | $35 | 5,698,866 | Apr 4, 2025 |
| Mar 25, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.45 | $36 | 5,698,874 | Apr 4, 2025 |
| Mar 26, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.41 | $35 | 5,698,882 | Apr 4, 2025 |
| Mar 27, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.20 | $34 | 5,698,890 | Apr 4, 2025 |
| Mar 28, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.20 | $34 | 5,698,898 | Apr 4, 2025 |
| Mar 31, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.29 | $34 | 5,698,906 | Apr 4, 2025 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $429 84 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,824 945 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,635 1,035 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $417 93 shares | +0% | |
| 14Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,548 875 shares | +0% | |
| 14Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $881 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.